Sun Pharma Plans $1.04B Rupee Debt Sale to Fund Organon Acquisition

Key Facts

1Sun Pharmaceutical Industries plans to raise around 100 billion rupees ($1.04 billion) through a rupee-denominated debt sale.

2The debt sale proceeds will be used to partly fund a bridge loan taken to acquire the US healthcare firm Organon & Co.

Sun Pharmaceutical Industries plans to raise around 100 billion rupees ($1.04 billion) through a rupee-denominated debt sale. Reuters reported that the proceeds from the bond issuance will be used to partly fund a bridge loan taken to acquire the US healthcare firm Organon & Co.

The company seeks to replace short-term bridge financing with longer-term local currency debt to optimize its financing structure following the acquisition. Regarding related equity performance, OGN closed at $13.73 on September 28, 2026, having traded between a day high of $13.75 and a low of $13.72 during that session.